Art. -Nr.: HY-171006

IRF1-IN-1

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

IRF1-IN-1 (Compound I-2) is an IRF1 inhibitor. IRF1-IN-1 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-1 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1). IRF1-IN-1 has a protective effect on ionizing radiation-induced inflammatory skin injury.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.72%
CAS. Nr.: 701225-07-2
Formel: C₂₂H₂₄N₄O₄S
Molecular Weight:440.52

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

IRF1-IN-1 Chemical Structure

CAS. Nr.: 701225-07-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

PARP-1

IL-1

Caspase-1

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle PARP Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

In Vitro

IRF1-IN-1 pretreatment (20 μM, 12 h) decreases the recruitment of IRF1 to the promoter of CASP1 in irradiated HaCaT cells (20 Gy)^[1].
IRF1-IN-1 (20 μM, 24 h) attenuates the NSP-10 plasmid transfection-induced IRF1 activation in HELF, HaCaT and WS1 cells^[1].
IRF1-IN-1 (50 μM, 24 h) treatment reduces the transcriptional activity of IRF1 in HELF cells 96 h after SARS-CoV-2 pseudovirus infection^[1].
IRF1-IN-1 decreases radiation (20 Gy)-induced cell death in K150 cells^[1].
IRF1-IN-1 maintains mitochondrial activity and ROS production in skin cells in the early stage after irradiation^[1].
IRF1-IN-1 significantly inhibits the cell death signaling pathway, i.e., suppresses cleavage of Caspase 1, GSDMD, IL-1 and PARP1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

IRF1-IN-1 pretreatment (100 μg/d, s.c., one every other day before irradiation) has a potential protective effect in 35 Gy radiation-induced inflammatory skin injury mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Radiogenic skin injury mice (intraperitoneal injection of pentobarbital sodium (1%, 30 mg/kg), 35 Gy at the dose rate of 1000 cGy/min by a 6-MeV electron beam)^[1]
Dosage:

100 μg/d
Administration:

Subcutaneous injection (s.c.), one every other day before irradiation, pretreatment
Result:

Showed a significant reduction in acute skin inflammatory manifestations, such as erythema and exudation and accelerated the healing process.
Showed protective effects on the function and structural integrity of radiation-induced lesions to the claws.

Chemical Information

CAS. Nr. 701225-07-2
Appearance Solid
Molecular Weight 440.52
Formel C₂₂H₂₄N₄O₄S
Color White to off-white
SMILES

O=C1C2=C(N=CN1CCC(NC3=CC=C(S(=O)(N4CCCCC4)=O)C=C3)=O)C=CC=C2
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (1)

All

Sort by:

Journal Impact Factor

J Inflamm Res

Integrated Multi-Omics Analysis Reveals IRF1-Driven Microglial PANoptosis via ZBP1 in Spinal Cord Injury. [Abstract]

2026 Mar 16:19:574990. PMID: 41867458

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 83.33 mg/mL (189.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2700 mL

11.3502 mL

22.7004 mL

5 mM

0.4540 mL

2.2700 mL

4.5401 mL

10 mM

0.2270 mL

1.1350 mL

2.2700 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 8 mg/mL (18.16 mM); Clear solution

This protocol yields a clear solution of ≥ 8 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (80.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 8 mg/mL (18.16 mM); Clear solution

This protocol yields a clear solution of ≥ 8 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (80.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Geng, et al. Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response. Cell Mol Immunol. 2024 Aug;21(8):856-872. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2700 mL	11.3502 mL	22.7004 mL	56.7511 mL
	5 mM	0.4540 mL	2.2700 mL	4.5401 mL	11.3502 mL
	10 mM	0.2270 mL	1.1350 mL	2.2700 mL	5.6751 mL
	15 mM	0.1513 mL	0.7567 mL	1.5134 mL	3.7834 mL
	20 mM	0.1135 mL	0.5675 mL	1.1350 mL	2.8376 mL
	25 mM	0.0908 mL	0.4540 mL	0.9080 mL	2.2700 mL
	30 mM	0.0757 mL	0.3783 mL	0.7567 mL	1.8917 mL
	40 mM	0.0568 mL	0.2838 mL	0.5675 mL	1.4188 mL
	50 mM	0.0454 mL	0.2270 mL	0.4540 mL	1.1350 mL
	60 mM	0.0378 mL	0.1892 mL	0.3783 mL	0.9459 mL
	80 mM	0.0284 mL	0.1419 mL	0.2838 mL	0.7094 mL
	100 mM	0.0227 mL	0.1135 mL	0.2270 mL	0.5675 mL

Keywords

IRF1-IN-1

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

IRF1-IN-1

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) IRF1-IN-1

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle PARP Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

IRF1-IN-1 Related Classifications

HY-171006 Related Classifications